RHOA and neoplasm: Previous studies have shown that treatment with paeoniflorin (10, 15, 20, or 40 μM) suppresses hepatocyte growth factor-induced migration and invasion and actin cytoskeleton rearrangement in glioblastoma cells, by inhibiting c-Met-mediated RhoA/ROCK signaling and EMT in U87, U251, and T98G cells or in the U87 xenograft mouse model, thereby reducing tumor size (Figure 9) (Wang et al., 2018d; Yu et al., 2019a).